Español
EnglishShow all projects
- Novomar-Centro Multipolar de Valorização de Recursos e Residuos Marinhos
A Valorização dos recursos e subprodutos marinhos das pescas através de desenvolvimentos biomédicos e o marco onde o projeto NOVOMAR e o Centro Multipolar de Valorização estão localizados. Portanto se adota uma visão mas ampla do conceito de valorização: “Utilizar subprodutos das pescas que são sub-utilizados para obter produtos de alto valor acrescentado bem que outros organismos marinhos que baixo condições particulares aumentam as suas propriedades ou se convertem em uma fonte de moléculas e compostos em certos campos da indústria”.
Ficha del proyecto
Title
Novomar-Centro Multipolar de Valorização de Recursos e Residuos Marinhos
Lead Partner
Universidade do Minho
Funding source
FEDER-POCTEP
Lifetime
2007 - 2013
Abstract
A Valorização dos recursos e subprodutos marinhos das pescas através de desenvolvimentos biomédicos e o marco onde o projeto NOVOMAR e o Centro Multipolar de Valorização estão localizados. Portanto se adota uma visão mas ampla do conceito de valorização: “Utilizar subprodutos das pescas que são sub-utilizados para obter produtos de alto valor acrescentado bem que outros organismos marinhos que baixo condições particulares aumentam as suas propriedades ou se convertem em uma fonte de moléculas e compostos em certos campos da indústria”.
- Iberomare-Centro Multipolar de Valorização de Recursos e Resíduos Marinhos
O projeto IBEROMARE visa a criação de um Centro Multipolar Objetivos principais:
Criação de um Centro Multipolar que visa encontrar alternativas de valorização de recursos marinhos e resíduos da indústria pesqueira, aquacultura e alimentar (processamento de peixe e algas). Em termos mas específicos os objetivos do IBEROMARE são: Aumentar o valor acrescentado dos recursos naturais das rías, zonas costeiras e bacias fluviais dentro das áreas envolvidas; Promover a interação networking entre o tecido empresarial e as instituições de I+D; Fomentar atividades de I+D em um setor tradicional da economia; Estabelecer um cronograma de ações públicas de disseminação do conhecimento gerado
Ficha del proyecto
Title
Iberomare-Centro Multipolar de Valorização de Recursos e Resíduos Marinhos
Lead Partner
Universidade do Minho - 3Bs Research Group
Funding source
INTERREG 0330_IBEROMARE_1_P Programa Operacional de Cooperaçao Transfronteiriça Espanha - Portugal 2007-2013 Área de Cooperaçao Norte de Portugal - Galiza
Lifetime
2007 - 2013
Abstract
O projeto IBEROMARE visa a criação de um Centro Multipolar Objetivos principais:
Criação de um Centro Multipolar que visa encontrar alternativas de valorização de recursos marinhos e resíduos da indústria pesqueira, aquacultura e alimentar (processamento de peixe e algas). Em termos mas específicos os objetivos do IBEROMARE são: Aumentar o valor acrescentado dos recursos naturais das rías, zonas costeiras e bacias fluviais dentro das áreas envolvidas; Promover a interação networking entre o tecido empresarial e as instituições de I+D; Fomentar atividades de I+D em um setor tradicional da economia; Estabelecer um cronograma de ações públicas de disseminação do conhecimento gerado
- BIOTECMAR-Exploração biotecnológica de produtos e subprodutos marinhos
Criação de uma rede integral para a produção de ingredientes de alto valor acrescentado a partires dos recursos marinhos atlânticos. BIOTECMAR dará apoio às PMEs da área atlântica para desenvolver a utilização das biotecnologias modernas e contribuir para à diversificação das atividades derivadas da explotação de biomassa marinha no marco estrito da gestão sustentável dos recursos naturais marinhos
Ficha del proyecto
Title
BIOTECMAR-Exploração biotecnológica de produtos e subprodutos marinhos
Lead Partner
Universidade de Bretagne Occidentale (UEB-UBO)
Funding source
Fondos FEDER – INTERREG IIIB
Lifetime
2007 - 2013
Abstract
Criação de uma rede integral para a produção de ingredientes de alto valor acrescentado a partires dos recursos marinhos atlânticos. BIOTECMAR dará apoio às PMEs da área atlântica para desenvolver a utilização das biotecnologias modernas e contribuir para à diversificação das atividades derivadas da explotação de biomassa marinha no marco estrito da gestão sustentável dos recursos naturais marinhos
- CVMAR-Centro Multipolar de Valorização
O Centro Multipolar de Valorização de Recursos e Resíduos Marinhos – http://cvmar.cetmar.org/ - tem como missão servir de organismo consultivo e de apoio às empresas, administrações e instituições públicas e privadas sobre valorização de recursos e subprodutos de origem marinha aplicada aos sectores alimentar, cosmético, biomédico, farmacêutico e ambiental.
Ficha del proyecto
Title
CVMAR-Centro Multipolar de Valorização
Lead Partner
Universidade do Minho - Grupo 3B's
Funding source
Fundos FEDER - Programa POCTEP
Lifetime
2007 - 2013
Abstract
O Centro Multipolar de Valorização de Recursos e Resíduos Marinhos – http://cvmar.cetmar.org/ - tem como missão servir de organismo consultivo e de apoio às empresas, administrações e instituições públicas e privadas sobre valorização de recursos e subprodutos de origem marinha aplicada aos sectores alimentar, cosmético, biomédico, farmacêutico e ambiental.
- MARMED-Desenvolvimento de produtos biomédicos inovadores procedentes da valorização dos recursos marinhos
O projeto MARMED tem como objetivo a valorização de resíduos marinhos e subprodutos em aplicações biomédicas, e em estreita colaboração com indústrias, que avalia o potencial de mercado das aplicações, a serem desenvolvidas e/ou estudadas. MARMED tem a ambição de permitir a exploração contínua, sustentável e economicamente viável dos recursos das regiões costeiras e bacias fluviais e da aquicultura, aumentando o valor acrescentado de muitos componentes destes recursos. Pretende desenvolver tecnologias ecológicas para a conversão de resíduos em produtos com aplicação industrial, através do estabelecimento de métodos simples, eficientes e economicamente viáveis de extração e purificação das substâncias encontradas na flora/fauna marinha e fluvial e na aquicultura.
Ficha del proyecto
Title
MARMED-Desenvolvimento de produtos biomédicos inovadores procedentes da valorização dos recursos marinhos
Lead Partner
Universidade do Minho-Grupo 3B's
Funding source
INTERREG-Espaço Atlântico
Lifetime
2007 - 2013
Abstract
O projeto MARMED tem como objetivo a valorização de resíduos marinhos e subprodutos em aplicações biomédicas, e em estreita colaboração com indústrias, que avalia o potencial de mercado das aplicações, a serem desenvolvidas e/ou estudadas. MARMED tem a ambição de permitir a exploração contínua, sustentável e economicamente viável dos recursos das regiões costeiras e bacias fluviais e da aquicultura, aumentando o valor acrescentado de muitos componentes destes recursos. Pretende desenvolver tecnologias ecológicas para a conversão de resíduos em produtos com aplicação industrial, através do estabelecimento de métodos simples, eficientes e economicamente viáveis de extração e purificação das substâncias encontradas na flora/fauna marinha e fluvial e na aquicultura.
- VALBIOMAR-Valorização biotecnológica dos recursos marinhos
Valorização biotecnológica dos recursos marinhos através da utilização dos organismos marinhos e os subprodutos das pescas para obter compostos com atividade biológica para a aplicação na indústria da alimentação animal e humana, a cosmética e a farmacêutica transferindo a tecnologia às PME's
Ficha del proyecto
Title
VALBIOMAR-Valorização biotecnológica dos recursos marinhos
Lead Partner
Universidade de La Rochelle
Funding source
Fundos FEDER-INTERREG IIIB
Lifetime
2007 - 2013
Abstract
Valorização biotecnológica dos recursos marinhos através da utilização dos organismos marinhos e os subprodutos das pescas para obter compostos com atividade biológica para a aplicação na indústria da alimentação animal e humana, a cosmética e a farmacêutica transferindo a tecnologia às PME's
- MarPipe is a Research and Training Network of 11 academic and industrial partners based in 8 European countries working in collaboration to train young researchers in the field of marine drug-discovery. This consortium aims at improving the feasibility of using marine natural products in drug discovery programmes by overcoming the historical and complex bottlenecks, such as low quantities of secondary metabolites, supply issue of biological samples, cultivability and low microbial chemodiversity in standard lab conditions, difficulties in isolation, chemical structure elucidation of compounds, early and reliable validation of bioactivity and the best mechanisms of flow-through into exploitation. Marpipe will give trainning 11 ESRs in marine drug-discovery, providing these researchers with unique skills toward becoming world leaders in this research field and to advance their careers in academia or industry. MarPipe PhDs will be trained in a programme including training-by-research, joint courses of technical, scientific and transferrable skills, active participation to public scientific events, and an intense inter-sectoral networking exchange plan. Marine organisms have the capacity to produce a variety of biologically potent natural products, including antibiotic and anticancer compounds. MarPipe aims at further development of antimicrobial and anticancer lead compounds originating from a previous EU project (PharmaSea), and will also explore the bioactivity of deep-sea samples (5000m) collected during the recent Eurofleet-2 project in the sub-Antarctic. The PhD students will thus be involved in all phases of the drug discovery pipeline, from isolation of new microbial strains to pre-clinical development of lead compounds. Importantly, they will also be trained to overcome existing bottlenecks in the field, e.g. low yields and low chemodiversity, isolation of known compounds, toxicity of compounds. The discovery rates of new bioactive antimicrobial and anticancer molecules will be enhanced through 11 PhD projects that cover all phases of the biodiscovery pipeline. As a final outcome of the project, we envisage the creation of a marine biodiscovery start-up company, which will include most of the MarPipe partners. The scientists of the future will be trained to become conscious about the socio-economic and policy context of their work, since several specific MarPipe PhD projects focus on legal, policy, innovation and entrepreneurship themes
Ficha del proyecto
Title
Lead Partner
Funding source
Lifetime
2016 - 2020
Abstract
MarPipe is a Research and Training Network of 11 academic and industrial partners based in 8 European countries working in collaboration to train young researchers in the field of marine drug-discovery. This consortium aims at improving the feasibility of using marine natural products in drug discovery programmes by overcoming the historical and complex bottlenecks, such as low quantities of secondary metabolites, supply issue of biological samples, cultivability and low microbial chemodiversity in standard lab conditions, difficulties in isolation, chemical structure elucidation of compounds, early and reliable validation of bioactivity and the best mechanisms of flow-through into exploitation.
Marpipe will give trainning 11 ESRs in marine drug-discovery, providing these researchers with unique skills toward becoming world leaders in this research field and to advance their careers in academia or industry. MarPipe PhDs will be trained in a programme including training-by-research, joint courses of technical, scientific and transferrable skills, active participation to public scientific events, and an intense inter-sectoral networking exchange plan.
Marine organisms have the capacity to produce a variety of biologically potent natural products, including antibiotic and anticancer compounds. MarPipe aims at further development of antimicrobial and anticancer lead compounds originating from a previous EU project (PharmaSea), and will also explore the bioactivity of deep-sea samples (5000m) collected during the recent Eurofleet-2 project in the sub-Antarctic. The PhD students will thus be involved in all phases of the drug discovery pipeline, from isolation of new microbial strains to pre-clinical development of lead compounds. Importantly, they will also be trained to overcome existing bottlenecks in the field, e.g. low yields and low chemodiversity, isolation of known compounds, toxicity of compounds.
The discovery rates of new bioactive antimicrobial and anticancer molecules will be enhanced through 11 PhD projects that cover all phases of the biodiscovery pipeline. As a final outcome of the project, we envisage the creation of a marine biodiscovery start-up company, which will include most of the MarPipe partners. The scientists of the future will be trained to become conscious about the socio-economic and policy context of their work, since several specific MarPipe PhD projects focus on legal, policy, innovation and entrepreneurship themes
- The GHaNA project aims to explore and characterize a new marine bioresource, for blue biotechnology applications in aquaculture, cosmetics and possibly food and health industry. The project will determine the biological and chemical diversity of Haslea diatoms to develop mass-scale production for viable industrial applications by maximising biomass production and associated high-value compound production, including terpenoids, marennine-like pigments, lipids and silica skeletons. The genus Haslea species type H. ostrearia, produces marennine, a water-soluble blue pigment used for greening oysters in Western France, which is also a bioactive molecule. Haslea diatoms have thus a high potential for use in (1) existing oyster farming, (2) production of pigments and bioactive compounds with natural antibacterial properties, (3) application as a colouring agent within industry, and (4) use of silica skeletons as inorganic “biocharges” in the formulation of new elastomeric materials. This will be achieved through fundamental and applied-oriented research to isolate fast- growing strains of Haslea, optimising their growth environment to increase marennine and other high-value compound productivity; to develop blue biotechnology specifically applied to benthic microalgae (biorefinery approach, processes); and to develop industrial exploitation of colouring and bioactive compounds through commercial activities of aquaculture, food, cosmetics and health
Ficha del proyecto
Title
Lead Partner
Funding source
Lifetime
2017 - 2021
Abstract
The GHaNA project aims to explore and characterize a new marine bioresource, for blue biotechnology applications in aquaculture, cosmetics and possibly food and health industry. The project will determine the biological and chemical diversity of Haslea diatoms to develop mass-scale production for viable industrial applications by maximising biomass production and associated high-value compound production, including terpenoids, marennine-like pigments, lipids and silica skeletons. The genus Haslea species type H. ostrearia, produces marennine, a water-soluble blue pigment used for greening oysters in Western France, which is also a bioactive molecule. Haslea diatoms have thus a high potential for use in (1) existing oyster farming, (2) production of pigments and bioactive compounds with natural antibacterial properties, (3) application as a colouring agent within industry, and (4) use of silica skeletons as inorganic “biocharges” in the formulation of new elastomeric materials. This will be achieved through fundamental and applied-oriented research to isolate fast- growing strains of Haslea, optimising their growth environment to increase marennine and other high-value compound productivity; to develop blue biotechnology specifically applied to benthic microalgae (biorefinery approach, processes); and to develop industrial exploitation of colouring and bioactive compounds through commercial activities of aquaculture, food, cosmetics and health
- ABACUS gathers 2 large industries, 3 algae SMEs and 4 RTOs. It aims at a business-oriented and technology-driven development of a new algal biorefinery, thereby bringing to the market innovative algae-based ingredients for high-end applications, spanning from algal terpenes for fragrances to long-chain terpenoids (carotenoids) for nutraceuticals and cosmetic actives. One key objective of ABACUS is to obtain more than 10% photosynthates of targeted terpenoids. For this purpose, ABACUS selects and optimizes unique algae strains from 4 large culture collections owned by project’s partners. Moreover, ABACUS focuses on optimizing cultivation steps and mastering production of target products by online monitoring and automated control of photobioreactors with the development of specific sensors for terpenes and for the parameters relevant to terpene’s production (light, PO2, PCO2, nutrients). ABACUS investigates the fractionation steps to provide green low-cost downstream processing with a view to reduce operational expenses of the whole production line. Life cycle analysis and techno-economic analysis are fundamental guidelines of ABACUS’s developments to ensure that technologies and products are economically and environmentally sustainable. Applicability of targeted ingredients is assessed by the industrial partners (SMEs and large industries with established access to markets) considering cosmetic and nutraceutical applications. ABACUS aims to demonstrate biorefining processes allowing valorizing up to 95% of the algal biomass into high value ingredients and by-products. EU standards and market regulations associated to innovative bioprocesses and new ingredients are reviewed in order to demonstrate the acceptability of the ABACUS biorefinery. ABACUS key advantage lies in its business-oriented workplan, gathering key players along the whole product development chain and incorporating most-advanced technologies for efficient growth and fractionation of microalgae.
Ficha del proyecto
Title
Lead Partner
Funding source
Lifetime
2017 - 2020
Abstract
ABACUS gathers 2 large industries, 3 algae SMEs and 4 RTOs. It aims at a business-oriented and technology-driven development of a new algal biorefinery, thereby bringing to the market innovative algae-based ingredients for high-end applications, spanning from algal terpenes for fragrances to long-chain terpenoids (carotenoids) for nutraceuticals and cosmetic actives. One key objective of ABACUS is to obtain more than 10% photosynthates of targeted terpenoids. For this purpose, ABACUS selects and optimizes unique algae strains from 4 large culture collections owned by project’s partners. Moreover, ABACUS focuses on optimizing cultivation steps and mastering production of target products by online monitoring and automated control of photobioreactors with the development of specific sensors for terpenes and for the parameters relevant to terpene’s production (light, PO2, PCO2, nutrients). ABACUS investigates the fractionation steps to provide green low-cost downstream processing with a view to reduce operational expenses of the whole production line. Life cycle analysis and techno-economic analysis are fundamental guidelines of ABACUS’s developments to ensure that technologies and products are economically and environmentally sustainable. Applicability of targeted ingredients is assessed by the industrial partners (SMEs and large industries with established access to markets) considering cosmetic and nutraceutical applications. ABACUS aims to demonstrate biorefining processes allowing valorizing up to 95% of the algal biomass into high value ingredients and by-products. EU standards and market regulations associated to innovative bioprocesses and new ingredients are reviewed in order to demonstrate the acceptability of the ABACUS biorefinery. ABACUS key advantage lies in its business-oriented workplan, gathering key players along the whole product development chain and incorporating most-advanced technologies for efficient growth and fractionation of microalgae.
- Microalgae are a source of secondary metabolites useful as new bioactive compounds. The antibacterial activity of a few microalgae extracts has been reported. However, neither isolation nor characterization of the compounds responsible of the activity observed has been achieved. Most importantly, activity of microalgae extracts on biofilm formation has not been determined yet. Biofilm formation is especially important in infections and tissue inflammation related to implants and catheters. These problems finally cause a release of the implant, which must be removed and replaced by a new one, entailing an increase in antibiotic consumption, together with a health costs of 50,000-90,000 € per infection episode. The overall objective of NOMORFILM project is to search for antibiofilm compounds isolated from microalgae that will be useful in the treatment of this kind of infections and could be incorporated in the manufacturing of medical prosthetic devices. Most industrially interesting antibiofilm molecules will be incorporated into nanoparticles in order to develop manufacturing methodologies able to incorporate these compounds into real prosthetic devices matrixes. Several objectives in the project deal with improving directly the health of the EU citizens as well as the associated health cost, by generating potential new drug candidates to combat important health problems as prosthetic devices biofilm infections. This implies that efforts trying to reduce the percentage of prosthetic devices replaced due to biofilm infection will play an important role at a socioeconomic level: less money invested in replacement of implants and in antimicrobial treatments, and fewer expenses associated to hospitalization days.
Ficha del proyecto
Title
Lead Partner
Funding source
Lifetime
2015 - 2019
Abstract
Microalgae are a source of secondary metabolites useful as new bioactive compounds. The antibacterial activity of a few microalgae extracts has been reported. However, neither isolation nor characterization of the compounds responsible of the activity observed has been achieved. Most importantly, activity of microalgae extracts on biofilm formation has not been determined yet. Biofilm formation is especially important in infections and tissue inflammation related to implants and catheters. These problems finally cause a release of the implant, which must be removed and replaced by a new one, entailing an increase in antibiotic consumption, together with a health costs of 50,000-90,000 € per infection episode. The overall objective of NOMORFILM project is to search for antibiofilm compounds isolated from microalgae that will be useful in the treatment of this kind of infections and could be incorporated in the manufacturing of medical prosthetic devices.
Most industrially interesting antibiofilm molecules will be incorporated into nanoparticles in order to develop manufacturing methodologies able to incorporate these compounds into real prosthetic devices matrixes. Several objectives in the project deal with improving directly the health of the EU citizens as well as the associated health cost, by generating potential new drug candidates to combat important health problems as prosthetic devices biofilm infections. This implies that efforts trying to reduce the percentage of prosthetic devices replaced due to biofilm infection will play an important role at a socioeconomic level: less money invested in replacement of implants and in antimicrobial treatments, and fewer expenses associated to hospitalization days.
- The overall objective of BIOSEA is the development and validation of innovative, competitive and cost-effective upstream and downstream processes for the cultivation of 3 microalgae (Spirulina platensis, Isochrysis galbana and Nannochloropsis sp.), and 2 macroalgae (Ulva ohnoi and Saccharina latissima) to produce and extract at least 6 high value active principles at low cost (up to 55% less than with current processes) to be used in food, feed and cosmetic/personal care as high-added value products. The innovation will be on applying them on algae or in combination with other techniques for recovery of multiple compounds from the same feedstock, which will require technological adjustment & optimizations. BIOSEA process will be effective and environmental friendly and the compounds will be obtained at low cost and will be used in food, feed and cosmetic/personal care markets. By this way, the industrialization of the process could be addressed once the project ends
Ficha del proyecto
Title
Lead Partner
Funding source
Lifetime
2017 - 2020
Abstract
The overall objective of BIOSEA is the development and validation of innovative, competitive and cost-effective upstream and downstream processes for the cultivation of 3 microalgae (Spirulina platensis, Isochrysis galbana and Nannochloropsis sp.), and 2 macroalgae (Ulva ohnoi and Saccharina latissima) to produce and extract at least 6 high value active principles at low cost (up to 55% less than with current processes) to be used in food, feed and cosmetic/personal care as high-added value products.
The innovation will be on applying them on algae or in combination with other techniques for recovery of multiple compounds from the same feedstock, which will require technological adjustment & optimizations.
BIOSEA process will be effective and environmental friendly and the compounds will be obtained at low cost and will be used in food, feed and cosmetic/personal care markets. By this way, the industrialization of the process could be addressed once the project ends
- The biotechnology of microalgae has gained considerable importance in recent decades, as they represent a largely untapped reservoir of novel and valuable bioactive compounds. The biological and chemical diversity of the microalgae, has been the source of unique bioactive molecules with the potential for industrial development as pharmaceuticals, cosmetics, nutritional supplements. The proposed project will combine both basic and applied research in the fields of –omics technologies, biochemistry, applied and enzyme biotechnology in order to exploit microalgae resources for the development: 1) Natural UV sunscreens, based on algae mycosporine-like aminoacids, 2) Algae-based nutraceuticals as functional foods and food supplements, 3) Algae-derived proteases with applications in cosmetic (skin repair enzymes) and food industry. The implementation of the project will offer to the involved academic and SMSs the opportunity to translate scientific research into well defined knowledge-based ‘green’ products and analytical tools. Apart from scientific objectives, the project will enhance the European’s capacity in the field of Blue Growth and Marine Biotechnology by exchanging interdisciplinary knowledge, developing and disseminating joint research activities, thus strengthening the intersectoral links between academia and industry for sustainable growth.
Ficha del proyecto
Title
Lead Partner
Funding source
Lifetime
2018 - 2021
Abstract
The biotechnology of microalgae has gained considerable importance in recent decades, as they represent a largely untapped reservoir of novel and valuable bioactive compounds. The biological and chemical diversity of the microalgae, has been the source of unique bioactive molecules with the potential for industrial development as pharmaceuticals, cosmetics, nutritional supplements. The proposed project will combine both basic and applied research in the fields of –omics technologies, biochemistry, applied and enzyme biotechnology in order to exploit microalgae resources for the development: 1) Natural UV sunscreens, based on algae mycosporine-like aminoacids, 2) Algae-based nutraceuticals as functional foods and food supplements, 3) Algae-derived proteases with applications in cosmetic (skin repair enzymes) and food industry. The implementation of the project will offer to the involved academic and SMSs the opportunity to translate scientific research into well defined knowledge-based ‘green’ products and analytical tools. Apart from scientific objectives, the project will enhance the European’s capacity in the field of Blue Growth and Marine Biotechnology by exchanging interdisciplinary knowledge, developing and disseminating joint research activities, thus strengthening the intersectoral links between academia and industry for sustainable growth.
- Genis is based in Siglufjördur, a village in the North Iceland traditionally focused on the fishing industry. After the fishery crisis worsen in 2008, Siglufjördur started to pay attention to the marine biotechnology, with Genis at the forefront. Hence, since 2002, we develop health products based in T-ChOS™ (Therapeutic Chitooligosaccharides), which are compounds obtained from chitin extracted from the North Atlantic shrimp exoskeleton. T-ChOS™ show a strong anti-inflammatory effect based in a novel biological pathway discovered by Genis: Inhibition of the YKL-40 chitinase enzyme, whose levels are very high in several diseases as cancer. Our in vitro, in vivo and human studies prove that T-ChOS™ can decrease inflammation and enhance tumour response to chemotherapy. During the Ph1 project, we confirmed the feasibility of developing a nutraceutical based on T-ChOS™ to use as an adjuvant to chemotherapy in cancer patients. In this Ph2 project, we aim to optimise manufacturing, validate through a clinical trial and bring to market SIMECOS: A nutraceutical for cancer patients derived from chitin purified T-ChOS™ molecules. SIMECOS targets lung, breast and pancreatic cancer patients, with survival rates after 5-year of 20%, 82.2% and 5.2%, respectively. SIMECOS is expected to increase their quality of life, thanks to its proven effects to decrease pain and fatigue. The high trends (30%-95%) among cancer patients to use complementary supplements entail a great business opportunity for SIMECOS as in Europe, there are more than 780,000 patients per year diagnosed with breast, pancreatic and lung cancer looking for solutions to decrease chemotherapy side effects and improve the effectiveness of their treatment. Clinically validated SIMECOS will help these patients. We expect SIMECOS to reach the market in 2020.
Ficha del proyecto
Title
Lead Partner
Funding source
Lifetime
2018 - 2020
Abstract
Genis is based in Siglufjördur, a village in the North Iceland traditionally focused on the fishing industry. After the fishery crisis worsen in 2008, Siglufjördur started to pay attention to the marine biotechnology, with Genis at the forefront. Hence, since 2002, we develop health products based in T-ChOS™ (Therapeutic Chitooligosaccharides), which are compounds obtained from chitin extracted from the North Atlantic shrimp exoskeleton. T-ChOS™ show a strong anti-inflammatory effect based in a novel biological pathway discovered by Genis: Inhibition of the YKL-40 chitinase enzyme, whose levels are very high in several diseases as cancer. Our in vitro, in vivo and human studies prove that T-ChOS™ can decrease inflammation and enhance tumour response to chemotherapy. During the Ph1 project, we confirmed the feasibility of developing a nutraceutical based on T-ChOS™ to use as an adjuvant to chemotherapy in cancer patients. In this Ph2 project, we aim to optimise manufacturing, validate through a clinical trial and bring to market SIMECOS: A nutraceutical for cancer patients derived from chitin purified T-ChOS™ molecules. SIMECOS targets lung, breast and pancreatic cancer patients, with survival rates after 5-year of 20%, 82.2% and 5.2%, respectively. SIMECOS is expected to increase their quality of life, thanks to its proven effects to decrease pain and fatigue. The high trends (30%-95%) among cancer patients to use complementary supplements entail a great business opportunity for SIMECOS as in Europe, there are more than 780,000 patients per year diagnosed with breast, pancreatic and lung cancer looking for solutions to decrease chemotherapy side effects and improve the effectiveness of their treatment. Clinically validated SIMECOS will help these patients. We expect SIMECOS to reach the market in 2020.
- New generations of devices for tissue engineering (TE) should rationalize better the physical and biochemical cues operating in tandem during native regeneration, in particular at the scale/organizational-level of the stem cell niche. The understanding and the deconstruction of these factors (e.g. multiple cell types exchanging both paracrine and direct signals, structural and chemical arrangement of the extra-cellular matrix, mechanical signals…) should be then incorporated into the design of truly biomimetic biomaterials. ATLAS proposes rather unique toolboxes combining smart biomaterials and cells for the ground-breaking advances of engineering fully time-self-regulated complex 2D and 3D devices, able to adjust the cascade of processes leading to faster high-quality new tissue formation with minimum pre-processing of cells. Versatile biomaterials based on marine-origin macromolecules will be used, namely in the supramolecular assembly of instructive multilayers as nanostratified building-blocks for engineer such structures. The backbone of these biopolymers will be equipped with a variety of (bio)chemical elements permitting: post-processing chemistry and micro-patterning, specific/non-specific cell attachment, and cell-controlled degradation. Aiming at being applied in bone TE, ATLAS will integrate cells from different units of tissue physiology, namely bone and hematopoietic basic elements and consider the interactions between the immune and skeletal systems. These ingredients will permit to architect innovative films with high-level dialogue control with cells, but in particular sophisticated quasi-closed 3D capsules able to compartmentalise such components in a “globe-like” organization, providing local and long-range order for in vitro microtissue development and function. Such hybrid devices could be used in more generalised front-edge applications, including as disease models for drug discovery or test new therapies in vitro.
Ficha del proyecto
Title
Lead Partner
Funding source
Lifetime
2015 - 2020
Abstract
New generations of devices for tissue engineering (TE) should rationalize better the physical and biochemical cues operating in tandem during native regeneration, in particular at the scale/organizational-level of the stem cell niche. The understanding and the deconstruction of these factors (e.g. multiple cell types exchanging both paracrine and direct signals, structural and chemical arrangement of the extra-cellular matrix, mechanical signals…) should be then incorporated into the design of truly biomimetic biomaterials. ATLAS proposes rather unique toolboxes combining smart biomaterials and cells for the ground-breaking advances of engineering fully time-self-regulated complex 2D and 3D devices, able to adjust the cascade of processes leading to faster high-quality new tissue formation with minimum pre-processing of cells. Versatile biomaterials based on marine-origin macromolecules will be used, namely in the supramolecular assembly of instructive multilayers as nanostratified building-blocks for engineer such structures. The backbone of these biopolymers will be equipped with a variety of (bio)chemical elements permitting: post-processing chemistry and micro-patterning, specific/non-specific cell attachment, and cell-controlled degradation. Aiming at being applied in bone TE, ATLAS will integrate cells from different units of tissue physiology, namely bone and hematopoietic basic elements and consider the interactions between the immune and skeletal systems. These ingredients will permit to architect innovative films with high-level dialogue control with cells, but in particular sophisticated quasi-closed 3D capsules able to compartmentalise such components in a “globe-like” organization, providing local and long-range order for in vitro microtissue development and function. Such hybrid devices could be used in more generalised front-edge applications, including as disease models for drug discovery or test new therapies in vitro.
- The objective of SponGES is to develop an integrated ecosystem-based approach to preserve and sustainably use vulnerable sponge ecosystems of the North Atlantic. The SponGES consortium, an international and interdisciplinary collaboration of research institutions, environmental non-governmental and intergovernmental organizations, will focus on one of the most diverse, ecologically and biologically important and vulnerable marine ecosystems of the deep-sea - sponge grounds – that to date have received very little research and conservation attention. Our approach will address the scope and challenges of EC’s Blue Growth Call by strengthening the knowledge base, improving innovation, predicting changes, and providing decision support tools for management and sustainable use of marine resources. SponGES will fill knowledge gaps on vulnerable sponge ecosystems and provide guidelines for their preservation and sustainable exploitation. North Atlantic deep-sea sponge grounds will be mapped and characterized, and a geographical information system on sponge grounds will be developed to determine drivers of past and present distribution. Diversity, biogeographic and connectivity patterns will be investigated through a genomic approach. Function of sponge ecosystems and the goods and services they provide, e.g. in habitat provision, bentho-pelagic coupling and biogeochemical cycling will be identified and quantified. This project will further unlock the potential of sponge grounds for innovative blue biotechnology namely towards drug discovery and tissue engineering. It will improve predictive capacities by quantifying threats related to fishing, climate change, and local disturbances. SpongeGES outputs will form the basis for modeling and predicting future ecosystem dynamics under environmental changes. SponGES will develop an adaptive ecosystem-based management plan that enables conservation and good governance of these marine resources on regional and international levels.
Ficha del proyecto
Title
Lead Partner
Funding source
Lifetime
2016 - 2020
Abstract
The objective of SponGES is to develop an integrated ecosystem-based approach to preserve and sustainably use vulnerable sponge ecosystems of the North Atlantic. The SponGES consortium, an international and interdisciplinary collaboration of research institutions, environmental non-governmental and intergovernmental organizations, will focus on one of the most diverse, ecologically and biologically important and vulnerable marine ecosystems of the deep-sea - sponge grounds – that to date have received very little research and conservation attention. Our approach will address the scope and challenges of EC’s Blue Growth Call by strengthening the knowledge base, improving innovation, predicting changes, and providing decision support tools for management and sustainable use of marine resources. SponGES will fill knowledge gaps on vulnerable sponge ecosystems and provide guidelines for their preservation and sustainable exploitation. North Atlantic deep-sea sponge grounds will be mapped and characterized, and a geographical information system on sponge grounds will be developed to determine drivers of past and present distribution. Diversity, biogeographic and connectivity patterns will be investigated through a genomic approach. Function of sponge ecosystems and the goods and services they provide, e.g. in habitat provision, bentho-pelagic coupling and biogeochemical cycling will be identified and quantified. This project will further unlock the potential of sponge grounds for innovative blue biotechnology namely towards drug discovery and tissue engineering. It will improve predictive capacities by quantifying threats related to fishing, climate change, and local disturbances. SpongeGES outputs will form the basis for modeling and predicting future ecosystem dynamics under environmental changes. SponGES will develop an adaptive ecosystem-based management plan that enables conservation and good governance of these marine resources on regional and international levels.